You have 9 free searches left this month | for more free features.

Condition

Advanced Cancer (1)

Carcinoma, Non-Small-Cell Lung (1)

Gastric Adenocarcinoma (1)

Gastroesophageal Junction Adenocarcinoma (1)

Hepatocellular Cancer (1)

Non-Small Cell Lung Cancer (1)

Renal Cell Carcinoma (1)

Overall Status

Completed (2)

Sign in for free

Phase

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Eli Lilly and Company (2)

Collaborator

Intervention

emibetuzumab (2)

erlotinib (1)

ramucirumab (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

emibetuzumab

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Boston, New York, Nashville

Completed

Has Results

Advanced Cancer
+5 more

Emibetuzumab
Ramucirumab

Boston, Massachusetts
+3 more

Nov 24, 2020

NSCLC Trial in Worldwide (Emibetuzumab, Erlotinib)

Completed

Has Results

Carcinoma, Non-Small-Cell Lung

Emibetuzumab
Erlotinib

Birmingham, Alabama
+58 more

Sep 6, 2019